Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LCR008
MIFTS: 41

Lacrimal Apparatus Disease

Categories: Eye diseases
Genes Tissues Related diseases Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lacrimal Apparatus Disease

About this section

MalaCards integrated aliases for Lacrimal Apparatus Disease:

Name: Lacrimal Apparatus Disease 12 15
Lacrimal Apparatus Diseases 73

Classifications:

MalaCards categories:
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1400
ICD10 33 H04 H04.9
ICD9CM 35 375 375.9
MeSH 44 D007766
NCIt 50 C26809
SNOMED-CT 68 31053003
UMLS 73 C0022904
Sources

Summaries for Lacrimal Apparatus Disease

About this section
MalaCards based summary : Lacrimal Apparatus Disease, also known as lacrimal apparatus diseases, is related to excessive tearing and staphylococcal toxic shock syndrome, and has symptoms including visual disturbance, eye manifestations and dacryops. An important gene associated with Lacrimal Apparatus Disease is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are NF-KappaB Family Pathway and T cell receptor signaling pathway. The drugs Hyaluronic acid and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include eye, lung and brain, and related phenotypes are homeostasis/metabolism and digestive/alimentary

Sources

Related Diseases for Lacrimal Apparatus Disease

About this section

Diseases related to Lacrimal Apparatus Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
# Related Disease Score Top Affiliating Genes
1 excessive tearing 11.5
2 staphylococcal toxic shock syndrome 10.3 IL1B TNF
3 subacute cutaneous lupus erythematosus 10.3 TNF TRIM21
4 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL6 TNF
5 critical limb ischemia 10.3 IL6 TNF
6 juvenile ankylosing spondylitis 10.3 IL6 TNF
7 leukomalacia 10.3 IL6 TNF
8 periodontitis, chronic 10.3 IL1B IL6
9 cardiogenic shock 10.3 IL6 TNF
10 streptococcal toxic-shock syndrome 10.3 IL6 TNF
11 recurrent corneal erosion 10.3 IL1B IL6
12 bagassosis 10.3 IL1B IL6
13 paraneoplastic syndromes 10.3 IL1B IL6
14 tungiasis 10.3 IL10 TNF
15 microscopic polyangiitis 10.3 IL10 TNF
16 multifocal choroiditis 10.3 IL10 TNF
17 acute transverse myelitis 10.3 IL10 IL6
18 overnutrition 10.3 IL6 TNF TRPV1
19 exudative glomerulonephritis 10.3 IL1B TNF
20 cerebral palsy 10.3 IL1B IL6 TNF
21 punctate inner choroidopathy 10.3 IL10 TNF
22 synovitis 10.3 IL1B IL6 TNF
23 periodontal disease 10.3 IL1B IL6 TNF
24 juvenile rheumatoid arthritis 10.3 IL1B IL6 TNF
25 monocytic leukemia 10.3 IL1B IL6 TNF
26 cytomegalovirus infection 10.3 IL1B IL6 TNF
27 scorpion envenomation 10.3 IL6 TNF
28 dental pulp disease 10.2 IL1B TNF TRPV1
29 burning mouth syndrome 10.2 IL6 TNF TRPV1
30 plasmodium falciparum malaria 10.2 IL10 TLR9 TNF
31 pulmonary tuberculosis 10.2 IL10 TLR9 TNF
32 glossitis 10.2 IL1B IL6 TNF
33 laryngitis 10.2 IL1B IL6 TNF
34 acute vascular insufficiency of intestine 10.2 IL1B IL6 TNF
35 demyelinating disease 10.2 IL10 IL1B TNF
36 osteosclerotic myeloma 10.2 IL1B IL6 TNF
37 poems syndrome 10.2 IL1B IL6 TNF
38 periapical periodontitis 10.2 IL1B IL6 TNF
39 hypersensitivity reaction type iii disease 10.2 IL6 TLR9 TNF
40 rosacea 10.2 IL6 TNF TRPV1
41 stachybotrys chartarum 10.2 IL1B IL6 TNF
42 endometrial disease 10.2 IL1B IL6 TNF
43 tropical endomyocardial fibrosis 10.2 IL10 TNF
44 kawasaki disease 10.2 IL10 IL6 TNF
45 endomyocardial fibrosis 10.2 IL10 TNF
46 endometritis 10.2 IL1B IL6 TNF
47 joint disorders 10.2 IL1B IL6 TNF
48 adult-onset still's disease 10.2 IL1B IL6 TNF
49 dengue shock syndrome 10.2 IL1B IL6 TNF
50 acute respiratory distress syndrome 10.2 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Lacrimal Apparatus Disease:



Diseases related to Lacrimal Apparatus Disease
Sources

Symptoms & Phenotypes for Lacrimal Apparatus Disease

About this section

UMLS symptoms related to Lacrimal Apparatus Disease:


visual disturbance, eye manifestations, dacryops

MGI Mouse Phenotypes related to Lacrimal Apparatus Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.93 AQP5 AREG HSPG2 IL10 IL1B IL6
2 digestive/alimentary MP:0005381 9.91 AQP5 AREG HSPG2 IL10 IL6 MUC5AC
3 immune system MP:0005387 9.73 AREG CLEC4F HSPG2 IL10 IL1B IL6
4 integument MP:0010771 9.23 AREG HSPG2 IL10 IL1B IL6 TNF
Sources

Drugs & Therapeutics for Lacrimal Apparatus Disease

About this section

Drugs for Lacrimal Apparatus Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
6
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
7
Povidone Approved Phase 4,Not Applicable 9003-39-8
8
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
9
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
12 Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
13
Azithromycin Approved Phase 4 83905-01-5 55185 447043
14
Ketorolac Approved Phase 4,Phase 2 66635-83-4, 74103-06-3 3826
15
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
16 sodium fluoride Approved Phase 4,Not Applicable 7681-49-4
17
Allantoin Approved Phase 4,Not Applicable 97-59-6 204
18
Menthol Approved Phase 4 2216-51-5 16666
19
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6
20
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
21
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
22
Dipivefrin Approved Phase 4,Phase 3,Phase 1 52365-63-6 3105
23
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
24
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
25
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
26
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
27
Ofloxacin Approved Phase 4 82419-36-1 4583
28
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
29
Tacrolimus Approved, Investigational Phase 4,Not Applicable 104987-11-3 445643 439492
30
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
31
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
32
Sorbitol Approved Phase 4,Not Applicable 50-70-4 5780
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-02-9 14985
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 11103-57-4, 68-26-8 445354
36
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 5280795 6221
37
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 5881
38
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
39
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
40
Betaine Approved, Nutraceutical Phase 4,Not Applicable 107-43-7 247
41
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
42 Gallopamil Investigational Phase 4 16662-47-8
43 Tocotrienol Investigational Phase 4,Not Applicable 6829-55-6
44 Rebamipide Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90098-04-7
45
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
46
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
47 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Viscosupplements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 647)
# Name Status NCT ID Phase Drugs
1 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
2 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
3 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
4 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
5 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
6 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
7 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
8 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
9 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
10 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
11 The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora Completed NCT01010659 Phase 4
12 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
13 A Phase 4 Study Investigating the Efficacy of Retaineâ„¢ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaineâ„¢
14 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
15 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
16 A Safety and Efficacy Study of OPTIVE FUSIONâ„¢ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
17 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
18 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
19 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
20 Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase Completed NCT00520260 Phase 4 bromfenac;ketorolac
21 Tear Lipid Layer Thickness With Emollient Eye Drops Completed NCT03380624 Phase 4 Refresh Optive;Refresh Optimum OMEGA 3
22 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
23 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
24 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
25 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
26 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
27 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4
28 Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Completed NCT00909324 Phase 4 Pre-LASIK 0.3% hypromellose;Post-LASIK 0.3% hypromellose
29 Systane Clinical Experience Study Completed NCT00818909 Phase 4
30 Efficacy and Acceptability of Two Lubricant Eye Drops Completed NCT00756678 Phase 4 Lubricant Eye Drops (Optiveâ„¢);Lubricating Eye Drops (blink® Tears)
31 Refractive Surgery and Optive Compatibility Study Completed NCT00469157 Phase 4 Optive
32 Soothe Versus Refresh Completed NCT00284999 Phase 4 Soothe;Refresh Tears
33 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
34 The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
35 Comparison Between Rebamipide 2% Versus Autologous Serum Completed NCT03608761 Phase 4 Rebamipide
36 Quality of Life and Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
37 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
38 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
39 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
40 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
41 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
42 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
43 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
44 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
45 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
46 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
47 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
48 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
49 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
50 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)

Search NIH Clinical Center for Lacrimal Apparatus Disease

Sources

Genetic Tests for Lacrimal Apparatus Disease

About this section
Sources

Anatomical Context for Lacrimal Apparatus Disease

About this section

MalaCards organs/tissues related to Lacrimal Apparatus Disease:

41
Eye, Lung, Brain, Bone, Colon, Heart, Lymph Node
Sources

Publications for Lacrimal Apparatus Disease

About this section
Sources

Variations for Lacrimal Apparatus Disease

About this section
Sources

Expression for Lacrimal Apparatus Disease

About this section
Search GEO for disease gene expression data for Lacrimal Apparatus Disease.
Sources

Pathways for Lacrimal Apparatus Disease

About this section

Pathways related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
NF-KappaB Family Pathway 64
Show member pathways
 12.64 AREG IL1B IL6 TLR9 TNF
2
T cell receptor signaling pathway 37
Show member pathways
 12.36 IL10 IL1B IL6 TNF
3
IL-17 Family Signaling Pathways 65
Show member pathways
 12.27 IL1B IL6 MUC5AC TNF
4
Toll Comparative Pathway 64
Show member pathways
 12.24 HSPG2 IL1B IL6 TNF
5
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.18 AREG IL10 IL1B IL6 TNF
6
IL-1 Family Signaling Pathways 65
Show member pathways
 12.15 IL1B IL6 MUC5AC TNF
7
Tuberculosis 37
12.15 IL10 IL1B IL6 TLR9 TNF
8
Bacterial infections in CF airways 22
Show member pathways
 12.12 IL1B IL6 TLR9 TNF
9
C-type lectin receptor signaling pathway 37
Show member pathways
 12.11 IL10 IL1B IL6 TLR9 TNF
10
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.1 IL10 IL1B IL6 TNF
11
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.97 HSPG2 IL1B IL6 TNF
12
Th1 Differentiation Pathway 65
Show member pathways
 11.92 IL10 IL1B IL6 TLR9 TNF
13
Interleukin-4 and 13 signaling 66
11.91 IL10 IL1B IL6 TNF
14
AGE-RAGE signaling pathway in diabetic complications 37
11.83 IL1B IL6 TNF
15
Hematopoietic cell lineage 37
11.82 IL1B IL6 TNF
16
Amoebiasis 37
11.82 IL10 IL1B IL6 TNF
17
Rheumatoid arthritis 37
11.79 IL1B IL6 TNF
18
Innate Lymphoid Cell Differentiation Pathways 65
11.72 IL10 IL1B TNF
19
Pertussis 37
11.71 IL10 IL1B IL6 TNF
20
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.66 IL10 IL1B IL6 TNF
21
Lung fibrosis 1
11.61 IL1B IL6 TNF
22
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.6 IL1B IL6 TNF
23
Legionellosis 37
11.53 IL1B IL6 TNF
24
Interleukin-10 signaling 66
11.42 IL10 IL1B IL6 TNF
25
Dendritic Cells Developmental Lineage Pathway 65
11.42 IL10 IL1B IL6 TLR9 TNF
26
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.41 IL1B IL6 TNF
27
Antifolate resistance 37
11.23 IL1B IL6 TNF
28
IL-10 Pathway 64
11.21 IL10 IL1B IL6 TNF
29
G-protein signaling_RhoB regulation pathway 22
11.15 IL10 IL1B IL6 TNF
30
Development and heterogeneity of the ILC family 1
11.13 AREG IL1B IL6 TNF
31
Malaria 37
11.04 IL10 IL1B IL6 TLR9 TNF
32
Cytokines and Inflammatory Response 1
11.02 IL10 IL1B IL6 TNF
33
G-protein signaling_Rap2B regulation pathway 22
10.9 AREG HSPG2 IL10 IL1B IL6 PPP1R12A
34
African trypanosomiasis 37
10.57 IL10 IL1B IL6 TLR9 TNF
Sources

GO Terms for Lacrimal Apparatus Disease

About this section

Cellular components related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 AREG HSPG2 IL10 IL1B IL6 LACRT
2 extracellular region GO:0005576 9.4 BPIFA2 DNASE1L1 HSPG2 IL10 IL1B IL6

Biological processes related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.95 AREG IL10 IL1B IL6 LACRT TNF
2 cellular response to lipopolysaccharide GO:0071222 9.92 IL10 IL1B IL6 TNF
3 defense response to bacterium GO:0042742 9.91 BPIFA2 IL10 LACRT TLR9 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.9 IL1B IL6 TLR9 TNF
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 AREG IL6 LACRT
6 positive regulation of JNK cascade GO:0046330 9.84 IL1B TLR9 TNF
7 response to peptide hormone GO:0043434 9.81 AREG IL1B TRPV1
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 IL1B TLR9 TNF
9 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 IL1B TNF TRPV1
10 positive regulation of JUN kinase activity GO:0043507 9.75 IL1B TLR9 TNF
11 negative regulation of interleukin-6 production GO:0032715 9.71 IL10 TLR9 TNF
12 positive regulation of interleukin-8 production GO:0032757 9.7 IL1B TLR9 TNF
13 negative regulation of growth of symbiont in host GO:0044130 9.68 IL10 TNF
14 response to molecule of bacterial origin GO:0002237 9.67 IL10 TLR9
15 negative regulation of neurogenesis GO:0050768 9.67 IL1B IL6 TNF
16 positive regulation of interleukin-6 production GO:0032755 9.67 IL1B IL6 TLR9 TNF
17 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.66 IL1B TLR9
18 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.65 TLR9 TNF
19 negative regulation of lipid storage GO:0010888 9.65 IL6 TNF
20 endothelial cell apoptotic process GO:0072577 9.65 IL10 TNF
21 positive regulation of DNA-binding transcription factor activity GO:0051091 9.65 IL10 IL1B IL6 TNF TRIM21
22 positive regulation of chemokine biosynthetic process GO:0045080 9.64 IL1B TNF
23 negative regulation of interleukin-8 production GO:0032717 9.64 IL10 TLR9
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 IL10 TNF
25 positive regulation of chemokine production GO:0032722 9.63 IL6 TLR9 TNF
26 positive regulation of fever generation GO:0031622 9.61 IL1B TNF
27 positive regulation of glial cell proliferation GO:0060252 9.61 IL1B IL6 TNF
28 chronic inflammatory response to antigenic stimulus GO:0002439 9.59 IL1B TNF
29 sequestering of triglyceride GO:0030730 9.58 IL1B TNF
30 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 IL10 IL1B TNF
31 fever generation GO:0001660 9.57 IL1B TRPV1
32 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 IL1B TNF
33 receptor biosynthetic process GO:0032800 9.55 IL10 TNF
34 regulation of establishment of endothelial barrier GO:1903140 9.5 IL1B PPP1R12A TNF
35 inflammatory response GO:0006954 9.5 HSPG2 IL10 IL1B IL6 TLR9 TNF
36 positive regulation of neuroinflammatory response GO:0150078 9.33 IL1B IL6 TNF
37 response to glucocorticoid GO:0051384 9.02 AREG IL10 IL1B IL6 TNF
38 immune response GO:0006955 10.06 IL10 IL1B IL6 TLR9 TNF

Molecular functions related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 AREG IL10 IL6 LACRT
2 interleukin-1 receptor binding GO:0005149 9.16 IL1B TLR9
3 cytokine activity GO:0005125 9.02 AREG IL10 IL1B IL6 TNF
Sources

Sources for Lacrimal Apparatus Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....